|
2025
|
Invention
|
Peptide analogs and methods of using the same. Provided herein are peptide analogs of gastrin rel... |
|
|
Invention
|
Gpr40 agonists.
This disclosure is directed, at least in part, to GPR40 agonists useful for the ... |
|
|
Invention
|
Nk3 modulators and uses thereof.
The present disclosure relates to compounds useful as modulator... |
|
2024
|
Invention
|
Crystalline gpr40 agonist and methods of making. Disclosed herein are crystalline GPR40 agonists ... |
|
|
Invention
|
Combination therapy for treatment of metabolic disease. Provided herein are methods and compositi... |
|
|
Invention
|
Gpr40 agonists. This disclosure is directed, at least in part, to GPR40 agonists useful for the t... |
|
|
Invention
|
Nk3 modulators and uses thereof. The present disclosure relates to compounds useful as modulators... |
|
|
Invention
|
Compositions comprising 4-({(4-cyclopropylisoquinolin-3-yl)[4-(trifluoromethoxy)benzyl]amino}sulf... |
|
2023
|
Invention
|
Combination therapies.
This disclosure is directed, at least in part, to combination therapies c... |
|
|
Invention
|
Ampk activators.
This disclosure is directed, at least in part, to AMPK activators useful for th... |
|
|
Invention
|
Gpr119 and gpr40 agonist combination therapies for gut-brain axis disorders. The present inventio... |
|
|
Invention
|
Treatment of headache disorders with nk3 modulators.
The present invention relates to a method f... |
|
|
Invention
|
Treatment of headache disorders with nk3 modulators. The present invention relates to a method fo... |
|
|
Invention
|
Systems and methods for associating genes with phenotypes. The present disclosure provides system... |
|
2022
|
Invention
|
Ampk activators. This disclosure is directed, at least in part, to AMPK activators useful for the... |
|
|
Invention
|
Compositions and methods for treating or preventing vasomotor symptoms.
The present disclosure i... |
|
|
Invention
|
Gpr119 agonists.
This disclosure is directed, at least in part, to GPR119 agonists useful for th... |
|
|
Invention
|
Gpr119 agonists. This disclosure is directed, at least in part, to GPR119 agonists useful for the... |
|
2021
|
Invention
|
Compositions for treating or preventing vasomotor symptoms.
The present disclosure is directed t... |
|
2020
|
Invention
|
Sstr5 antagonists.
This disclosure is directed, at least in part, to SSTR5 antagonists useful fo... |
|
|
Invention
|
Sstr5 antagonists. This disclosure is directed, at least in part, to SSTR5 antagonists useful for... |
|
|
Invention
|
Gpcr combination therapies.
This disclosure is directed, at least in part, to GPCR modulators in... |
|
|
Invention
|
Gpcr combination therapies. This disclosure is directed, at least in part, to GPCR modulators in ... |
|
2019
|
P/S
|
chemical or biochemical products, namely, small molecules, probiotic bacteria, probiotic bacteria... |
|
2018
|
P/S
|
Active chemical ingredients for use in the manufacture of pharmaceuticals for the treatment of ga... |
|
|
Invention
|
Compositions and methods for treating or preventing vasomotor symptoms. The present disclosure is... |
|
2017
|
Invention
|
Compositions for treating or preventing vasomotor symptoms. The present disclosure is directed to... |
